Teva Pharmaceuticals (NYSE:TEVA) has inked a non-exclusive licensing deal to use ProBioGen‘s human artificial lymph node technology in the preclinical testing of the pharma company’s drug candidates. ProBioGen, a contract developer and manufacturer based in Berlin, designed its 3D micro-organoid model for companies to use to predict the reactions that their drugs will provoke in the […]
